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Introduction
A critical event during tumorigenesis is the conversion from a 
static primary tumor to an invasive, disseminating metastasis. 
Moreover, tumor cells show an increased capacity to migrate. 
Numerous intracellular signaling molecules have been impli-
cated in migratory processes. Among them, the Rho GTPase 
family plays a pivotal role in regulating the biochemical and cyto-
skeletal pathways relevant to cell migration. The Rho GTPases 
Rac, Cdc42, and Rho control cell protrusions during migration. 
Aberrant regulation of Rho proteins is believed to associate with 
metastasis by promoting cell motility (Clark et al., 2000; Evers 
et al., 2000; Jaffe and Hall, 2002; Steeg, 2003).
The bona fi  de environment for migrating cells is the extra-
cellular matrix, which permits movement in a 3D scaffold that 
is biochemically complex and shows dynamic fl  exibility. 3D 
tissue culture models reconstitute an environment that resem-
bles the in vivo situation in regard to cell shape and movement. 
This model provides important insights into the mechanisms of 
cell motion during carcinogenesis. Recent advances have iden-
tifi  ed two modes of cell motility in 3D matrices. The elongated 
mode of migration is a consequence of Rac activity and gener-
ates membrane protrusions, the lamellipodia that drive motility. 
In contrast, a novel rounded mode of motility depends on RhoA 
and its main effector, Rho-associated coil-containing protein 
kinase (ROCK), and resembles the amoeboid movement. This 
involves a rounded bleb-associated movement that generates 
propulsive motion through the matrix independently of proteol-
ysis (Sahai and Marshall, 2003).
Curiously, genes encoding Rho GTPases are rarely found 
mutated in human cancers, in which only their functional ac-
tivities seem to be deregulated (Nakamoto et al., 2001; Rihet 
et al., 2001). This suggests that alterations in others genes 
  account for functional modifications of Rho GTPases ac-
companying actin cytoskeleton remodeling during metastasis. 
We hypothesize that this set of genes controls the cell cycle. 
Their mutation during the initiation phase in cancer would 
modify the behavior of proteins involved in actin cytoskeleton 
dynamics, such as Rho GTPases, leading to a migratory and 
invasive phenotype.
Beyond these genes is the tumor suppressor p53, whose 
mutations occurs in >50% of human tumors (Hollstein et al., 
1994). p53 protects cells from malignant transformation by 
regulating cell cycle arrest or by promoting apoptosis (Levine, 
1997; Giaccia and Kastan, 1998). We and others have recently 
shown that p53 modulates cell migration: p53 negatively 
modulates Rho GTPases and regulates cell polarization and 
migration (Gadea et al., 2002, 2004; Guo et al., 2003). How-
ever, little is known about the role of p53 in cells moving in 
a 3D matrix that mimics the in vivo microenvironment of 
 tumor  cells.
Identifying the mechanisms by which p53 modulates cell 
migration is important to understand how invasive cells arise. 
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n addition to its role in controlling cell cycle progression, 
the tumor suppressor protein p53 can also affect other 
cellular functions such as cell migration. In this study, we 
show that p53 deﬁ  ciency in mouse embryonic ﬁ  broblasts 
cultured in three-dimensional matrices induces a switch from 
an elongated spindle morphology to a markedly spherical 
and ﬂ  exible one associated with highly dynamic membrane 
blebs. These rounded, motile cells exhibit amoeboid-like 
movement and have considerably increased invasive prop-
erties. The morphological transition requires the RhoA–
ROCK (Rho-associated coil-containing protein kinase) 
pathway and is prevented by RhoE. A similar p53-mediated 
transition is observed in melanoma A375P cancer cells. 
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tributing to metastasis.
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In this study, we show that the elongated spindle-shaped fi  bro-
blastoid mode of motility can be converted to a rounded bleb-
bing movement by blocking p53 function. This amoeboid mode 
of motility requires RhoA–ROCK signaling and confers higher 
velocity and invasive properties to p53-defi  cient cells. Thus, the 
range of p53 tumor suppressor activity extends to the control of 
the mode of migration of invasive cells.
Results and discussion
p53
−/− ﬁ  broblasts show rounded 
blebbing movement
Initially, we compared the movement of p53-defi  cient primary 
mouse embryonic fi  broblasts (MEFs; p53
−/− MEFs) with that 
of wild-type (wt) MEFs cultured in 3D Matrigel matrix using 
time-lapse video microscopy. The migration of the two cell types 
is strikingly different (Fig. 1 A and Videos 1 and 2, available 
at http://www.jcb.org/cgi/content/full/jcb.200701120/DC1). 
wt MEF maintained a spindle-shaped elongated morphology, 
generated extensions, and moved slowly at 2 ± 1 μm/h
−1, 
whereas p53
−/− MEF moved as rounded cells using a transla-
tory motion in the direction of the serum growth factor gradient. 
They show many dynamic bleblike structures, alternating rapid 
cycles of squeezing and expansion, and considerable deform-
ability. p53
−/− cells moved at 12 ± 5 μm/h
−1, maintaining 
their rounded morphology. Expression of the GFP-tagged mu-
tant p53 H273, a dominant-negative form of p53, converts 
the elongated morphology of MEF to a marked spherical and 
fl  exible one associated with highly dynamic membrane blebs 
similar to those observed in p53
−/− MEFs (Fig. 1 B and Video 3). 
The expression of GFP-tagged wt p53 in p53
−/− MEFs inhibits 
dynamic blebbing and leads to an elongated morphology (Fig. 
1 B and Video 4), whereas that of GFP-tagged p53 H273 has no 
effect. Thus, the loss of wt p53 activity is suffi  cient to drive 
Figure 1.  Rounded blebbing movement is provoked 
by p53 deﬁ  ciency.  (A) Time-lapse analysis of MEFs 
and p53
−/− MEFs moving within Matrigel. Still DIC 
time-lapse images from accompanying videos of 
wt MEFs (Video 1) and p53
−/− MEFs (Video 2, avail-
able at http://www.jcb.org/cgi/content/full/jcb
.200701120/DC1). Cells were plated into a thick 
layer of Matrigel, and a gradient of serum growth fac-
tors was established. Frames show the cell migration 
at the indicated times. Arrows indicate the direction of 
cell movement. Dotted circles indicate the initial situa-
tion of the cell when the video starts. (B) Time-lapse 
analysis of the different modes of cell motility within 
Matrigel. DIC images of cells transfected with GFP-
tagged plasmids (to enable the identiﬁ  cation of trans-
fected cells as visualized in green) expressing either 
p53 H273 in MEFs (still images from Video 3), p53 wt 
in p53
−/− MEFs (still images from Video 4), or p53 
H273 in p53
−/− MEFs as control (right). Cells were 
plated within Matrigel as in A. (C) p53 regulates sub-
cellular distributions of integrin β1 and ezrin in rounded 
migrating cells. Representative integrin β1 and ezrin 
ﬂ  uorescent staining of MEFs and p53
−/− MEFs trans-
fected with p53 wt, p53 H273, siRNA p53, or plas-
mid EGFP. Insets show the covisualization of F-actin 
(red), GFP (green), and ezrin or integrin β1 (blue) as 
indicated. Cells were plated in Matrigel, and a gradient 
of serum growth factors was established. Arrows show 
the direction of cell movement in Matrigel. Bars, 10 μm.P53 DRIVES THE MODE OF CELLULAR MIGRATION • GADEA ET AL. 25
the switch from an elongated fi  broblast-like to a rounded type 
of migration.
In Matrigel, cells moving with a rounded or elongated mor-
phology show a distinct subcellular distribution of integrin β1 
and ezrin that helps in establishing the direction of movement 
(Sahai and Marshall, 2003). In Matrigel, rounded blebbing 
MEFs that arise from p53 inactivation show integrin β1 and ezrin 
relocalization to the moving front of the cell. A similar clustering 
was also observed in rounded p53
−/− MEFs. In contrast, conver-
sion of p53
−/− MEFs to elongated morphology by the expression 
of p53 wt led to their relocalization throughout the cell, notably 
in the newly formed long extensions (Fig. 1 C). Thus, p53 con-
trols the clustering of integrin β1 and ezrin in rounded cells.
Culture of fi  broblastic cells in monolayers imposes an arti-
fi  cial polarity between the lower and upper surface of these apo-
lar cells. Their morphology and migration change in a 3D matrix, 
suggesting that the spatial constraints and surrounding biochem-
ical microenvironment are a better approximation of the in vivo 
situation (Friedl and Brocker, 2000; Cukierman et al., 2001). 
This is particularly striking for p53-defi  cient MEFs that become 
blebbing spherical cells once suspended in 3D matrices, losing 
their initial fi  broblastoid morphology observed in 2D culture.
Figure 2.  p53 regulates RhoA activation. (A) GTPase activities in wt MEFs and p53
−/− MEFs. Cells were lysed 24 h after plating, and the levels of GTP-
bound RhoA, Rac1, and Cdc42 were assayed. (B) RhoA activity in transfected MEFs and p53
−/− MEFs. Cells transfected with p53 wt and p53 H273 were 
assayed for RhoA activity. (A and B) The values are the mean ± SD (error bars) of three independent experiments. (C–F) Representative F-actin and RhoA 
ﬂ  uorescent staining of wt MEFs and p53
−/− MEFs untreated (C), treated with TAT-C3 (F), or transfected with plasmids expressing either p53 wt (D) or p53 
H273 (E). Panels show phalloidin-stained F-actin (red) and RhoA labeling (green). Arrows point to blebbing structures. Bars, 10 μm.JCB • VOLUME 178 • NUMBER 1 • 2007  26
RhoA activity is enhanced in p53
−/− MEFs
This rounded blebbing movement observed in p53
−/− MEFs is 
strikingly similar to amoeboid-like motility, which is dependent 
on Rho–ROCK signaling in a 3D matrix (Sahai and Marshall, 
2003). We compared the level of GTP-bound RhoA in p53
−/− 
and wt MEFs. GTP-RhoA was increased 3.4-fold in p53
−/− 
MEFs, whereas GTP-Rac and Cdc42 were barely affected (Fig. 
2 A). This change was functional because protein expression 
levels were unaltered by p53 deletion. Reintroduction of wt p53 
in p53
−/− MEFs lowered the level of GTP-RhoA to that of wt 
MEFs (Fig. 2 B). Conversely, p53 H273 did not affect the over-
activation of RhoA in p53
−/− MEFs. Finally, blocking p53 in 
MEFs using p53 H273 or siRNA-mediated knockdown of p53 
was suffi  cient to increase GTP-RhoA (Fig. 2 B). These results 
show that wt p53 inhibits RhoA activation and has a role in reg-
ulating RhoA signaling pathways.
Distinct localization of RhoA in p53
−/− MEFs
Translocation from the cytoplasm to the membrane area is essen-
tial for both the activation and function of RhoA (Takaishi et al., 
1995). We compared the localization of RhoA and fi  lamentous 
actin (F-actin) in p53
−/− and wt MEFs. In wt MEFs, RhoA 
exhibits a punctuate distribution throughout the cytoplasm with 
a marked concentration in the perinuclear region. F-actin stress 
fi  bers cross the cytoplasm and accumulate slightly around the 
edge of the cell (Fig. 2 C, top). In p53
−/− MEFs, RhoA shows 
its punctuate cytoplasmic localization but is excluded from the 
perinuclear region (Fig. 2 C, bottom). Instead, RhoA colocal-
izes with large patches of polymerized actin in bleblike globular 
structures that are distributed over and protruding from the cell 
surface (Fig. 2 C, arrows). In addition, MEFs lacking p53 activ-
ity show more peripheral microspikes, which were previously 
characterized as fi  lopodia (Gadea et al., 2002). They also show 
an accumulation of peripheral polymerized actin bundles (i.e., a 
redistribution of F-actin stress fi  bers; Fig. 2 C). The expression 
of wt p53 led to loss of the bleblike protrusions and recovery of 
the punctuate RhoA localization in the perinuclear region. This 
was not seen with p53 H273, indicating that wt p53 activity is 
required for RhoA localization (Fig. 2, compare D with E). 
Treatment of p53
−/− MEFs with TAT-C3, which inactivates 
RhoA, RhoB, and RhoC (Coleman et al., 2001), abolished bleb-
like structures and led to RhoA redistribution in the perinuclear 
Figure 3.  ROCK activity is required for rounded 
blebbing morphology driven by p53 deﬁ  ciency. 
(A) Still DIC time-lapse images from Video 5 
(available at http://www.jcb.org/cgi/content/
full/jcb.200701120/DC1) of p53
−/− MEFs 
treated with Y27632. Frames show the spread-
ing of a p53
−/− MEF at the indicated times. 
(B) DIC images show wt MEFs cotransfected 
with GFP to identify transfected cells (insets) 
and ROCK-∆1 (still images from Video 6; Fig. S1) 
or with GFP alone as a control. (C) Represen-
tative F-actin and RhoA ﬂ  uorescent staining of 
wt MEFs and p53
−/− MEFs treated either with 
Y27632 or H1152. (D) Time-lapse analysis of 
different modes of cell motility within Matrigel. 
Still DIC images of MEFs transfected either 
with ROCK-∆1 (still DIC images from Video 7) 
or GFP alone as a control. (bottom) Still DIC 
images of p53
−/− MEFs treated with Y27632 
or H1152 and transfected with p53 H273 
(from Video 8 and Video 9, respectively). The 
transfected cells expressing either ROCK-∆1 
or p53 H273 are visualized using GFP. 
Cells were plated within Matrigel as in Fig. 1. 
Bars, 10 μm.P53 DRIVES THE MODE OF CELLULAR MIGRATION • GADEA ET AL. 27
region (Fig. 2 F). Thus, RhoA activation is required for bleb 
formation in p53
−/− cells.
p160 ROCK controls morphological 
changes observed in p53
−/− ﬁ  broblasts
RhoA-driven actin reorganization largely depends on the serine–
threonine protein kinase ROCK (Amano et al., 1997; Ishizaki 
et al., 1997). To determine whether ROCK mediates mem-
brane blebbing in p53
−/− MEFs cultured in monolayer, we 
used Y27632 and H1152, which are two distinct, structurally un-
related pharmacological inhibitors of ROCK. p53
−/− MEFs 
promptly lost their extensive dynamic bleblike activities and their 
rounded morphology within 40 min, adopting a fl  attened, spread 
shape when treated with Y27632 (Fig. 3 A and Video 5, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200701120/DC1) 
or H1152 (not depicted). Consistent with this, the expression of 
ROCK-∆1, an active mutant, in wt MEF promoted a rounded 
morphology accompanied by numerous dynamic bleblike ex-
tensions similar to p53
−/− MEF (Fig. 3 B and Video 6). GFP 
alone had no effect (Fig. 3 B). The spreading of p53
−/− MEFs 
induced by Y27632 or H1152 was accompanied by the reorga-
nization of F-actin from cortical bundles into scattered cyto-
plasmic dotlike structures concomitant with the loss of fi  lopo  dia 
(Fig. 3 C). Similar to other studies (Ishizaki et al., 2000; 
Totsukawa et al., 2000), ROCK inhibitors strongly reduced 
the number of stress fi  bers in both wt and p53
−/− MEFs. In 
addition, ROCK inhibition in p53
−/− MEFs led to RhoA relocal-
ization to the perinuclear region (compare Fig. 3 C with Fig. 
2 C). Thus, ROCK inhibition causes RhoA to lose its mem-
brane localization.
We tested whether ROCK activity is required for the 
rounded blebbing movement of p53
−/− MEFs cultured in Matrigel. 
Transfection of ROCK-∆1 converts MEFs from an elongated to 
a rounded blebbing morphology; GFP alone had no effect (Fig. 
3 D and Video 7, available at http://www.jcb.org/cgi/content/
full/jcb.200701120/DC1). In contrast, treatment of p53
−/− 
MEFs with Y27632 or H1152 inhibits dynamic blebbing and 
leads to an elongated morphology even upon the expression of 
p53 H273 (Fig. 3 D and Videos 8 and 9). This transition is ac-
companied by the redistribution of integrin β1 and ezrin to 
the moving front of the cell (Fig. S1). Thus, ROCK activity is 
required for the amoeboid-like rounded morphology driven by 
p53 defi  ciency.
Collectively, our results indicate that characteristics of the 
fi  broblast type of motility (i.e., that using elongation and trac-
tion) are lost when p53 function is abrogated using either p53 
H273 or siRNA. Cells adopt a rounded bleb morphology similar 
to that observed in p53
−/− MEFs cultured in 3D matrices. A p53 
defect leads to the aberrant overactivation of RhoA, which con-
sequently translocates to specifi  c membrane blebbing structures. 
Importantly, we show that the RhoA–ROCK signaling pathway 
is involved in p53-dependent morphological changes by modu-
lating round blebbing. It also appears to promote blebbing in 
p53
−/− cells. Notably, RhoA signaling through ROCK was pre-
viously shown to be important in the rounded blebbing move-
ment but not for the elongated protrusive movement of cancer 
cells cultured in 3D matrices (Sahai and Marshall, 2003).
Invasion of p53-deﬁ  cient cells requires 
ROCK activity and is prevented by RhoE
RhoA–ROCK signaling also plays a key role in invasion by 
blebbing cells moving in 3D matrix (Sahai and Marshall, 2003). 
Similarly, p53
−/− MEFs, which have an overactivation of this 
pathway, showed substantially higher invasiveness than wt 
MEFs in Matrigel (Fig. 4 A). Inhibition of Rho or ROCK by 
Figure 4.  p53 controls cell invasion through the RhoA–ROCK pathway. 
(A) Matrigel invasion of wt MEFs and p53
−/− MEFs. Cells were treated with 
either TAT-C3, Y27632, H1152, or protease inhibitors or were transfected 
with plasmids encoding either p53 wt, p53 H273, siRNA p53, ROCK-∆1, 
or RhoA-V14 as indicated. The changes in Matrigel invasion were ana-
lyzed as described in Materials and methods. For each data point, GFP-
positive cells were scored. (B) Representative RhoE and actin ﬂ  uorescent 
staining of p53
−/− MEFs transfected with GFP-RhoE. (C) DIC images of 
p53
−/− MEFs transfected with GFP-tagged RhoE (still images from Video 10, 
available at http://www.jcb.org/cgi/content/full/jcb.200701120/DC1). 
Cells were plated in Matrigel as in Fig. 1 A. (D) Matrigel invasiveness of 
p53
−/− MEFs transfected either with vector alone (control) or with RhoE. 
Quantiﬁ  cation was performed as in A. (A and D) Values are the means ± SD 
(error bars) of three independent experiments. Bars, 10 μm.JCB • VOLUME 178 • NUMBER 1 • 2007  28
treatment with TAT-C3, Y27632, or H1152 diminished the abil-
ity of p53
−/− MEFs to invade Matrigel by around 60%. Expres-
sion of wt p53 but not p53 H273 blocked this behavior.
The ability of MEFs to invade Matrigel was increased 
when p53 activity was blocked either by expression of the H273 
p53 mutant or using siRNA to p53 in MEFs. Similarly, invasive-
ness was enhanced by an active mutant of RhoA (RhoA-V14) 
and ROCK-∆1. Invasiveness of blebbing cells is independent of 
protease activities (Sahai and Marshall, 2003); accordingly, the 
invasive activity of p53
−/− MEFs was unaffected by the inhibi-
tion of proteases. Thus, the Rho–ROCK signaling module is 
necessary for the invasive behavior of p53
−/− cells in Matrigel.
RhoE, a member of the Rho family that blocks actin stress 
fi  bers (Guasch et al., 1998; Nobes et al., 1998), is a transcrip-
tional target of p53 in response to genotoxic stress; RhoE pro-
motes cell survival through the inhibition of ROCK1-mediated 
apoptosis (Ongusaha et al., 2006). The overexpression of RhoE 
clearly prevented actin polymerization and abolished the bleb-
like protrusions in p53
−/− MEFs, converting them to an elon-
gated morphology (Fig. 4, B and C; and Video 10, available at 
http://www.jcb.org/cgi/content/full/jcb.200701120/DC1). RhoE 
also considerably reduced the invasiveness of p53
−/− MEFs 
(Fig. 4 D), suggesting that RhoE helps mediate the control of 
cell morphology and invasiveness by p53.
p53 inactivation promotes rounded 
blebbing movement in A375P melanoma 
cancer cells
We sought to extend these observations to cancer cells. We chose 
A375P melanoma cells, which have a wt form of p53 and show an 
elongated mode of migration in 3D matrix (Sahai and Marshall, 
2003). Cell morphology was visualized using fl  uorescent wheat 
germ agglutinin, which provides highly selective labeling of the 
external plasma membrane. The expression of GFP-tagged p53 
H273 confers a rounded blebbing morphology to A375P cells, 
which associates with membrane blebs similar to those observed 
in p53
−/− MEFs (Fig. 5 A). In contrast, the elongated morphology 
of A375P was unchanged when p53 accumulation was induced 
by etoposide, which was verifi  ed using the induction of p21WAF, 
a transcriptional target of p53 (Fig. 5 B). These morphologic 
changes correlated with the level of GTP-RhoA, which was 
4.6-fold higher upon the expression of p53 H273 (Fig. 5 C). Thus, 
the amoeboid-like motility of A375P melanoma cells induced by 
the loss of p53 activity is dependent on RhoA activation.
Figure 5.  A375 melanoma cell invasiveness is regulated by p53 activity. (A) Confocal images of A375P cells expressing plasmid EGFP alone or p53 
H273. Cells were plated in Matrigel, and a gradient of serum growth factors was established to observe the mode of migration. The transfected cells are 
  visualized using GFP, and plasma membranes were labeled with ﬂ  uorescent WGA (wheat germ agglutinin; red). (B) p21 induction in A375P cells. A375P 
cells were untreated or treated with etoposide. Total protein lysates were analyzed by SDS-PAGE followed by immunoblot analysis using antibodies to p21. 
Normalization was performed with an anti–α-tubulin antibody. (C) RhoA activity in transfected A375P. Cells expressing GFP-tagged p53 H273 or plasmid 
EGFP (control) were compared for GTP-RhoA levels as in Fig. 2. The image is representative of three independent experiments. The values are the mean ± 
SD (error bars). (D) Invasiveness in 3D matrigel matrix of A375P-expressing p53 wt or p53 H273 treated with TAT-C3, Y27632, or H1152 as indicated. 
Results are expressed as in Fig. 4.P53 DRIVES THE MODE OF CELLULAR MIGRATION • GADEA ET AL. 29
Amoeboid cancer cell motility is particularly effi  cient in 
promoting the invasiveness of metastatic cells in 3D environ-
ments. Therefore, we performed invasion assays in Matrigel us-
ing this model. The expression of p53 H273 strongly increased 
the invasiveness of A375P, whereas wt p53 inhibited it (Fig. 5 D). 
TAT-C3, Y27632, or H1152 treatment largely reduced this re-
sponse in p53 H273–expressing A375P cells, arguing that mu-
tated p53 drives this behavior through RhoA–ROCK signaling. 
In contrast, protease inhibition did not alter p53 H273–driven 
invasiveness (Fig. 5 D). This stresses the role of the amoeboid-
like rounded morphology of p53-defi  cient A375P cells in their 
invasive potential.
Our results show that blocking p53 function is suffi  cient to 
convert melanoma cells to a rounded locomotion, indicating that 
cancer cells may also be subject to this regulation. This switch 
would favor the illegitimate dissemination of cancer cells con-
taining mutant p53, possibly increasing their invasiveness.
The tumor suppressor p53 is mutated in >50% of human 
cancers (Hollstein et al., 1994) and, thus, constitutes an appeal-
ing target for anticancer therapy. Diverse therapeutic strategies 
already exist that attempt to restore wt p53 function in cancer 
cells, including the rescue of mutant p53 function and reactiva-
tion of wt p53 (Blagosklonny, 2002). Given that there is no 
obvious selection for a metastatic phenotype, Bernards and 
Weinberg (2002) proposed that classic oncogenes and tumor 
suppressor genes implicated in the early stages of tumorigenesis 
may also play a role in metastasis. Our studies indicate that p53 
is an ideal candidate, as it is involved both in the control of 
tumor cell apoptosis and tumor cell invasion. This extends the 
applications for anticancer agents aimed at restoring p53 wt 
functions: such agents may combine antiproliferative and anti-
invasive activities.
Materials and methods
Cell culture, transfection, plasmids, reagents, and Rho GTPase 
activity assays
wt and p53
−/− MEFs were generated, cultured, and transfected as previ-
ously described (Gadea et al., 2002). A375P cells were cultured in DME 
with 10% FCS and transfected using electroporation (Nucleofector; 
Amaxa). In brief, 10
6 cells were suspended in 100 μl of solution R and 
mixed with 3 μg DNA for electroporation (program T-016). The primary 
antibodies used were anti-p21 (C-19; Santa Cruz Biotechnology, Inc.), 
anti-p53 (DO-1; Novocastra), and anti–α-tubulin (DM1A; Sigma-Aldrich). 
The inhibitors used were 10 μM Y27632 (Calbiochem) and 5 μM H1152 
(Calbiochem). Etoposide (Sigma-Aldrich) was used at 25 μg/ml
−1. GFP-
tagged p53 wt and p53 H273 were previously described (Gadea et al., 
2002). pSuper-siRNA p53 and plasmid EGFPC1-RhoE were gifts from 
J.-C. Bourdon (University of Dundee, Dundee, Scotland, UK) and Ph. Fort (Cen-
tre National de la Recherche Scientiﬁ  que, Montpellier, France), respectively. 
The Rho GTPase activities were processed as previously described (Gadea 
et al., 2002).
Invasion assay
The quantiﬁ  cation of cell invasion was performed in transwell cell culture 
chambers containing ﬂ   uorescence-blocking polycarbonate porous mem-
brane inserts (pore size of 8 μm; Fluoroblock; BD Biosciences). 100 μl 
Matrigel with reduced growth factors (a commercially prepared reconsti-
tuted basement membrane from Englebreth-Holm-Swarm tumors; BD Bio-
sciences) were prepared in a transwell. Cells were transfected and treated 
with TAT-C3 for 16 h and Y27632 or H1152 for 2 h as monolayer before 
trypsinization and plating (5 × 10
4) in serum-free media on top of a thick 
layer (around 500 μm) of Matrigel contained within the upper chamber of 
a transwell. Controls were left untreated. The upper and lower chambers 
were then ﬁ  lled with serum-free DME and DME with 10% FCS, respectively, 
thus establishing a soluble gradient of chemoattractant that permits cell in-
vasion throughout the Matrigel. Inhibitors were added immediately after 
cell plating at the aforementioned concentrations. Cells were allowed to in-
vade at 37°C and 5% CO2 through the gel for 36 h (for MEF and p53
−/− 
MEF) or for 24 h (for A375P) before ﬁ  xing for 15 min in 3.7% formalde-
hyde. Cells that had invaded through the Matrigel were detected on the 
lower side of the ﬁ  lter by GFP ﬂ  uorescence and counted for cell number. 
Six ﬁ  elds per ﬁ  lter were counted, and each assay was performed twice in 
triplicate for each cell line.
Immunoﬂ  uorescence
Cells were transfected and/or treated with TAT-C3, Y27632, or H1152 on 
coverslips at a conﬂ  uence of  30% before ﬁ  xation in 3.7% formaldehyde 
in PBS followed by a 5-min permeabilization in 0.1% Triton X-100 in PBS 
and were incubated in PBS containing 0.1% BSA before staining with pri-
mary antibodies as follows: RhoA (Santa Cruz Biotechnology, Inc.), anti-
ezrin polyclonal antibody (provided by P. Mangeat, Centre de Recherche en 
Biochimie Macromoléculaire, Montpellier, France), and integrin β1 (Santa 
Cruz Biotechnology, Inc.). All of the antibodies were revealed with either 
an AlexaFluor546- or -488–conjugated goat anti–mouse or anti–rabbit 
  antibody (Invitrogen and Interchim). Cells were stained for F-actin using 
TRITC-conjugated phalloidin (Sigma-Aldrich) or for membrane morphology 
using cell-impermeant AlexaFluor594 wheat germ agglutinin, which binds 
selectively to N-acetylglucosamin and N-acetylneuraminic (sialic) acid resi-
dues and provides highly selective labeling of the plasma membrane (Invit-
rogen). Cells were prepared as described previously (Gadea et al., 2002). 
Stacks of 16-bit ﬂ  uorescent images (z step of 0.1 μm) were captured with 
a MetaMorph-driven microscope (DMRB; Leica) using a 63× NA 1.4 Apo-
chromat oil immersion objective (Leica), a piezo stepper (E662; Physik In-
struments), and a camera (CoolSNAP HQ2; Photometrics). Epiﬂ  uorescence 
of all images (in 2D and 3D) were restored and deconvolved with Huygens 
(Scientiﬁ  c Volume Imaging) using the maximum likelihood estimation algo-
rithm. Restored stacks were processed with Imaris (Bitplane) for visualiza-
tion. The restored images were saved as tiff ﬁ  les that were mounted using 
Photoshop and Illustrator (Adobe).
Immunoﬂ  uorescence in 3D matrices
For immunoﬂ   uorescence of cells in 3D Matrigel network, cultures were 
transfected and treated with TAT-C3, Y27632, or H1152 as monolayer fol-
lowed by trypsinization and embedding into Matrigel in transwell cell cul-
ture chambers (as previously described in the Invasion assay section except 
that cells were allowed to invade through the gel for 6 h). Controls were 
left untreated. 50-μm cryosections were then cut at –20°C before ﬁ  xation 
in 4% PFA in PBS followed by a 2-min permeabilization in 0.5% Triton 
X-100. Immunolabeling with various antibodies was performed as in the pre-
vious section. Cells were analyzed using a microscope (LSM510 Meta; 
Carl Zeiss MicroImaging, Inc.) with a 63× NA 1.32 Apochromat water 
immersion objective (Carl Zeiss MicroImaging, Inc.) and a photomultiplica-
tor. Stacks of images were captured with LSM510 expert mode and were 
restored as described in the previous section.
Time-lapse imaging
Time-lapse microscopy was performed on an inverted microscope (DL IRBE; 
Leica) equipped with differential interference contrast (DIC) and GFP optics 
using a 63× NA 1.3 oil-immersion objective (Leica), sample heater (37°C), 
and a CO2 incubation chamber (Leica). Images were captured with a CCD 
camera (MicroMax 1300; Princeton Instruments) using MetaMorph 6 soft-
ware (Molecular Devices), converted to tiff ﬁ  les that were edited with 
ImageJ (National Institutes of Health), and compiled into QuickTime videos 
(Macintosh). The exposure time was set to 50 ms. All videos were recorded 
at the frequency of one image every 5 s.
For 3D videos, we devised home-made bicompartment chambers 
comprised of an 8-mm metal ring placed in the center of a 30-mm Petri 
dish. The cells were mixed with serum-free Matrigel, and the resultant sus-
pension was poured into the well formed by the metal ring. The assembly 
was placed in an incubator for 30 min while the Matrigel solidiﬁ  ed, after 
which the metal ring was removed. The resultant disc of Matrigel was sur-
rounded with 10% serum-complemented medium, taking care not to allow 
any medium to ﬂ  ow on top, thus exposing the cells to a lateral serum gra-
dient. Cells close to the periphery of the Matrigel disc were time lapsed to 
monitor their ability to migrate along the serum gradient. Z sections re-
corded over a series of time points were combined into QuickTime videos. 
Cell velocity (Fig. 1 A) was determined by measuring the speed of 10–12 
cells, and the values are the means of three independent experiments.JCB • VOLUME 178 • NUMBER 1 • 2007  30
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Video 1 shows MEFs move using an elongated mode of motility in 3D matrix. 
Video 2 shows p53
−/− MEFs move using a rounded mode of motility 
in 3D matrix. Video 3 shows that rounded blebbing movement is pro-
voked by p53 deﬁ   ciency in 3D matrix. Video 4 shows that elongated 
movement is driven by p53 activity in 3D matrix. Video 5 shows the 
spreading of a p53
−/− MEF treated with Y27632. Video 6 shows that 
ROCK-∆1 promotes a rounded morphology. Video 7 shows that rounded 
movement is promoted by ROCK-∆1 in 3D matrix. Videos 8 and 9 show 
that p53 deﬁ   ciency–driven rounded morphology depends on ROCK 
  activity in 3D matrix. Video 10 shows that p53 deﬁ   ciency–driven 
rounded morphology is prevented by RhoE in 3D matrix. Fig. S1 shows 
that ROCK mediates p53-dependent regulation of the subcellular distribu-
tion of inte  grin β1 and ezrin in rounded migrating cells cultured in 3D 
Matrigel. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200701120/DC1.
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